Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Top 20 Largest Publicly Traded Healthcare Companies

Page 1 of 5

In this article, we will be taking a look at the top 20 largest publicly traded healthcare companies. You can also check out 20 Fastest-Growing Health-Tech Companies in the World.

Major Players Driving the U.S. Healthcare Industry’s Growth and Innovation

The global healthcare industry is a massive and rapidly growing sector, valued at around $7.975 trillion as of 2023. According to the World Health Organization (WHO), at least half of the world’s population lacks access to essential health services. The U.S. healthcare industry is one of the largest and most complex in the world, accounting for nearly 20% of the country’s GDP. In 2021, 65% of the revenue in the US health industry came from patient care. However, the COVID-19 pandemic caused a significant drop in revenue, with the U.S. healthcare system’s revenue declining by around 50% in 2020.

Several healthcare companies play an important role in the US health industry. These companies include CVS Pharmacy, Johnson & Johnson, and Pfizer, among others.

CVS Health is a leading healthcare company in the United States, with over 9,000 retail locations across the United States. CVS Health’s PBM business helps manage prescription drug costs for millions of Americans, making medications more affordable and accessible. Their total revenues increased 11.9% to $93.8 billion in Q4,2023 and the total revenues increased 10.9% to $357.8 billion for the full year.

Similarly, Johnson and Johnson also plays an important role in US healthcare It is one of the largest healthcare stocks in the US. The company developed the first single-dose COVID-19 vaccine (Janssen COVID-19 Vaccine) in 2020. A large priority R&D pipeline with 64 projects, including 19 late-stage candidates targeting priority diseases like HIV/AIDS, tuberculosis, and viral hepatitis. All 19 late-stage candidates have access plans in place for low- and middle-income countries (LMICs). Commitment to supporting the control of soil-transmitted helminthiasis through mebendazole (Vermox) donations until 2025 in 51 countries. Their Q1 2024 reported sales grew 2.3% to $21.4 billion, with operational growth of 3.9% and adjusted operational growth of 4.0%. In the U.S., sales surged 7.8% to $11.6 billion in the same period.

The Booming Telemedicine Market and Rising Healthcare Costs: Global and U.S. Perspectives

One of the innovations that is most revolutionizing the field of digital health is telemedicine. With a predicted CAGR of 17.2% between 2023 and 2030, the global telemedicine market, which was valued at $87.41 billion in 2022, is projected to grow to $286.22 billion by 2030. With China aiming to build 20,000 hospitals in the next ten years to improve access to healthcare, global healthcare spending outside the US is predicted to expand more quickly than within the US. Considerable investment opportunities arise from rising medical inflation in the private sector in Brazil, where 75% of the population is covered by universal health care.

The expense of healthcare has been rapidly rising in the US. Everything increased in price by almost 81% between June 2023 and 2000, while healthcare expenditures increased by 114%. The COVID-19 epidemic has exacerbated the situation. COVID is becoming more and more like the flu, but treating and preventing it still comes with a high price tag. According to estimates from McKinsey, the US will pay an additional $200 billion annually on healthcare linked to COVID-19.

A medical technician in a lab coat overseeing a complex piece of healthcare technology equipment.

Our Methodology  

For our methodology, we have ranked the top largest publicly traded healthcare companies based on their current market caps.

Here is our list of the top 20 largest publicly traded healthcare companies.

20. Baxter 

Market Cap: $17.84 Billion 

Baxter, one of the largest healthcare companies, operates in two main business segments: BioScience and Medical Products. The company’s innovative technologies, such as the AMIA Automated Peritoneal Dialysis (APD) system and the Revaclear dialyzer, have significantly improved the quality of life for patients with end-stage renal disease. Their Q1 2024 revenue was $3.59 billion, up 2% year-over-year on a reported basis and up 4% on a constant currency basis, which surpassed analyst estimates of $3.553 billion. For full-year 2024, Baxter expects sales growth of approximately 2-3% on a constant currency basis and adjusted diluted EPS of $2.88 to $2.98.

19. Cardinal Health 

Market Cap: $23.98 Billion 

Cardinal Health is a leading healthcare services and products company, operating as a vital link in the healthcare supply chain. In response to the COVID-19 pandemic, Cardinal Health provided support to nonprofit partners, including United Way Worldwide, the Red Cross Society of China, and local organizations in Central Ohio. Cardinal Health is also committed to reducing its environmental impact. In 2022, the company signed the Health Sector Climate Pledge, setting a goal to reduce its Scope 1 and 2 greenhouse gas emissions and committing to set a Science-Based Target for Scope 1, 2, and 3 emissions.

18. Centene 

Market Cap: $41.83 Billion 

Centene is a Fortune 25 company headquartered in St. Louis, Missouri which serves as a major insurer of Medicaid, Medicare, and the Affordable Care Act exchange markets. The company successfully won 18 Medicaid procurements between October 2021 and December 2023, including contracts in two new states and seven new programs, expanding its reach to serve more members. In Q1,2024, they saw total revenues of $40.4 billion, with premium and service revenues of $36.3 billion, up 4% year-over-year. They also secured new Medicaid contracts in Oklahoma and Florida with continued services in Michigan during the same period.

17. Humana 

Market Cap: $42.85 Billion 

Humana is the second-largest provider of Medicare Advantage plans, serving over 5 million beneficiaries with high-quality coverage, and stands among the top healthcare companies in the world. Humana has been at the forefront of value-based care models, with close to 70% of its individual members enrolled in value-based primary care arrangements. Humana’s philanthropic arm, the Humana Foundation, has provided substantial grants to support mental health and nutrition programs for seniors and school-aged children. In 2023, the foundation awarded $4.9 million to Big Brothers Big Sisters of America to initiate and elevate mental health programs across multiple states.

16. CVS Health 

Market Cap: $72.05 Billion 

CVS Health is one of the largest healthcare companies in the US and it’s Caremark division is one of the largest pharmacy benefit managers (PBMs) in the country. It manages prescription drug plans for employers, health plans, and government programs, serving over 100 million plan members. In 2018, CVS Health acquired Aetna, a leading health insurance provider, for $69 billion. Their Total revenues increased to $357.8 billion, in 2023, up 10.9% compared to the prior year.

15. Gilead Sciences 

Market Cap: $84.59 Billion 

Gilead Sciences is one of the largest biopharmaceutical companies. Gilead’s antiretroviral drugs, such as Truvada and Genvoya, have revolutionized HIV treatment. The company’s breakthrough drug Sovaldi, in combination with other medications, has achieved remarkable cure rates for chronic hepatitis C, a previously difficult-to-treat condition. During the COVID-19 pandemic, Gilead’s antiviral drug remdesivir received emergency use authorization as a treatment option for hospitalized patients with severe COVID-19 infections. In Q1,2024 total revenue increased 5% year-over-year to $6.7 billion, driven by higher sales of HIV, oncology, and liver disease products.

14. HCA Healthcare 

Market Cap: $85.12 Billion 

HCA Healthcare and its affiliated HCA Healthcare Foundation have made substantial contributions to various community organizations and initiatives. In 2022, they donated over $44 million to organizations focused on disaster relief, health equity, access to healthcare careers, and community needs. This includes a $15 million collaboration with the American Heart Association to address health disparities and improve stroke care. HCA Healthcare has invested approximately $6.8 million towards its $10 million commitment to supporting Historically Black Colleges and Universities (HBCUs).

13. Bristol Myers Squibb 

Market Cap: $87.89 Billion 

Bristol Myers Squibb, one of the top largest publicly traded healthcare companies, has been at the forefront of developing groundbreaking treatments for various diseases which include cancer as well. The company Developed the first protease inhibitor for HIV/AIDS treatment. In Q1, 2024, their total revenues were $11.9 billion, an increase of 5% year-over-year.

12. Cigna 

Market Cap: $95.55 Billion 

Cigna has been at the forefront of efforts to make healthcare more affordable and accessible. Through its Evernorth Health Services segment, the company has saved patients and plans nearly $45 billion by improving pharmacy and medical spending for clients. In 2023, the company’s healthcare division invested $1 million in community-based organizations to provide over 3 million meals and improve access to fresh produce for seniors facing food insecurity.

11. Elevance Health 

Market Cap: $126.81 Billion 

In 2022, Elevance Health became the first managed care organization in the nation to earn the full three-year health equity accreditation from the National Committee for Quality Assurance (NCQA) for all of its owned Medicaid health plans, covering over 90% of its Medicaid membership. Elevance Health actively supports local communities through various initiatives, including over $84 million in active grants and sponsorships focused on maternal-child health, food as medicine, substance use disorder, and emergency relief. In Q1,2024, The company reported operating revenue of $42.3 billion, up 0.9% from Q1 2023.

10. Pfizer 

Market Cap: $161.83 Billion 

Pfizer, one of the best healthcare companies, invests heavily in research and development to bring new drugs and vaccines to market. In 2022, the company spent $11.42 billion on R&D. Pfizer developed the COVID-19 vaccine in partnership with BioNTech, which has been provided to more than 90 countries worldwide. In Q1 2024, their revenues totaled $14.9 billion, a 20% decrease year-over-year which could be due to lower sales of Comirnaty and Paxlovid. Excluding these COVID products, revenues grew 11% operationally.

9. Amgen 

Market Cap: $168.89 Billion 

Amgen stands ninth among the top largest publicly traded healthcare companies and has successfully brought to market several groundbreaking drugs, such as EPOGEN (epoetin alfa) for the treatment of anemia and NEUPOGEN (filgrastim) for the prevention of infections in cancer patients undergoing chemotherapy. Amgen reported total revenue of $7.45 billion in Q1 2024, a 22% increase from Q1 2023 and in line with analyst estimates. Their product sales grew 21.7% to $7.12 billion and Amgen’s rare disease portfolio, boosted by the Horizon Therapeutics acquisition, contributed nearly $1 billion in sales, up 14% year-over-year during the same period.

8. Abbott Laboratories 

Market Cap: $179.54 Billion 

Abbott Laboratories stands among the world’s largest healthcare companies. Abbott’s pharmaceutical division focuses on developing treatments for immunology, chronic kidney disease, and cardiovascular diseases. Some of their notable drugs include Humira, Creon, and Synthroid. Their notable devices include the FreeStyle Libre continuous glucose monitoring system and the MitraClip heart valve repair device. Abbott reported net earnings of $1.22 billion in Q1 2024, a 7% decrease from $1.31 billion in Q1 2023. Their revenue for Q1 2024 was $9.96 billion, up 2.2% from $9.74 billion in the same period last year.

7. Novartis 

Market Cap: $209.83 Billion 

Novartis has a strong presence in the US, with 14,890 full-time equivalent employees, including 5,250 employed at its US-based R&D sites. In 2021, the company invested USD 3.17 billion in R&D in the US, representing 33% of its global R&D spend of USD 9.54 billion. In 2021, Novartis received 8 FDA approvals, including new indications The company’s medicines reached over 750 million people globally, and in the US, 445,000 patients received free medication valued at over USD 13.5 billion through the Novartis Patient Assistance Foundation over the past five years

6. AstraZeneca 

Market Cap: $245.49 Billion 

AstraZeneca is a leading global biopharmaceutical company. One of AstraZeneca’s most prominent contributions is its commitment to advancing health equity in the US. Through its ACT on Health Equity initiative, the company has awarded over $3.3 million in financial contributions to 46 nonprofit organizations in 2024. In 2023, the company contributed $12 million in financial and non-financial donations through disaster relief and public health responses. In Q1 2024, their total Revenue increased 19% to $12,679 million, driven by an 18% rise in Product Sales and continued growth in Alliance Revenue from partnered medicines.

5. Abbvie 

Market Cap: $290.59 Billion 

AbbVie stands fifth among the top largest publicly traded healthcare companies and has a diverse pipeline of medicines targeting various diseases, including HIV/AIDS, oncology, mental health conditions, hepatitis C, endometriosis, and migraine. The company has 19 medicines in scope, with 14 on patent and two contraceptive methods. 37% of AbbVie’s medicines are on the WHO Essential Medicines List (EML). AbbVie reported Q1 2024 revenue of $12.31 billion, up 0.7% over Q1 2023. During the same period, AbbVie’s ex-Humira growth platform delivered a strong performance, with Skyrizi and Rinvoq revenues increasing 45.4% and 61.5% in the U.S., respectively

Page 1 of 5

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…